Latest Breaking News On - Sierra internal medicine - Page 4 : comparemela.com
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
IT News Online - AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
itnewsonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnewsonline.com Daily Mail and Mail on Sunday newspapers.
| Press Release
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers
Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects
OCALA, FL / ACCESSWIRE / December 24, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) announced today that the post-COVID-19 Long Hauler portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment. Eligible patients enrolled in the trial receive treatment with AIM s flagship pipeline drug Ampligen.